References
Korde LA, Zujewski JA, Kamin L et al (2010) Multidisciplinary meeting on male breast cancer summary and research recommendations. J Clin Oncol 28:2114–2122
Nahleh ZA, Srikantiah R, Safa M et al (2007) Male breast cancer in the veterans affairs population: a comparative analysis. Cancer 109:1471–1477
Giordano SH, Buzdar AU, Hortobagyi GN (2002) Breast cancer in men. Ann Intern Med 137:678–687
Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E (2012) Randomized phase II trial of everolimus in combination with tamoxifen inpatients with hormone receptor-positive, human epidermal growth factor receptor 2- negative metastatic breast cancer with prior exposure toaromatase inhibitors: a GINECO study. J Clin Oncol 30:2718–2724
Yardley DA, Noguchi S, Pritchard KI, Burris HA 3rd, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS (2013) Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 30:870–884
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kattan, J., Kourie, H.R. The use of everolimus to reverse tamoxifen resistance in men with metastatic breast cancer: a case report. Invest New Drugs 32, 1046–1047 (2014). https://doi.org/10.1007/s10637-014-0133-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-014-0133-2